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In 2003, seven organizations1 from around the world collaborated to 
create the Drugs for Neglected Diseases initiative (DNDi)—an 
organization to address the current imbalance in the development of drugs 
 
 1. Drugs for Neglected Diseases initiative (DNDi) was created by “the Oswaldo Cruz Foundation 
from Brazil, the Indian Council for Medical Research, the Kenya Medical Research Institute, the 
Ministry of Health of Malaysia and France’s Pasteur Institute; one humanitarian organization, Médecins 
sans Frontières (MSF); and one international research organization, the UNDP/World Bank/WHO’s 
Special Programme for Research and Training in Tropical Diseases.” The Drugs for Neglected Diseases 
Initiative – DNDi, WORLD HEALTH ORG., 
http://www.who.int/trypanosomiasis_african/partners/dndi/en/ (last visited May 3, 2016). 
 
242 CHICAGO-KENT JOURNAL OF INTELLECTUAL PROPERTY Vol 16:241 
for diseases affecting poor populations.2 While approximately $240.00 of 
public funding is spent per person on pharmaceutical research in developed 
countries, only $20.00 is spent per person in developing countries, and only 
$6.00 per head in sub-Saharan Africa.3 This public funding significantly 
incentivizes manufacturers in developed countries to research and develop 
new treatments, while the lack thereof impedes drug development in less 
developed countries.4 
Once a new drug is on the market, the cost of developing the drug is 
more likely to be recovered in developed nations, where patients have 
higher incomes and can afford treatment. In contrast, potential customers in 
poorer countries are unlikely to be able to pay a price for the drug that will 
allow the manufacturer to recoup the cost of developing it.5 This lack of 
support for research and development has contributed to over seventeen 
diseases in developing countries being neglected by research efforts.6 In 
fact, drugs that treat diseases that are more prevalent in the developed 
world, such as cancers and conditions of the central nervous system, are 
thirteen times more likely to be developed than a drug for a neglected 
disease, such as a parasitic disease.7 For example, 1393 new chemical 
compounds were authorized worldwide between 1975 and 1999, but only 
sixteen of these were for tropical diseases.8 
In May 2013, the World Health Organization’s 66th World Health 
Assembly adopted resolution WHA66.12, in which Member States 
resolved to enhance efforts to reduce the worldwide impact of neglected 
tropical diseases (NTD), with a specific focus on completely eradicating 
two NTDs by 2020.9 The criteria listed for a disease to qualify as a NTD 
includes: (1) the disease is disproportionately prevalent among people 
 
 2. DRUGS FOR NEGLECTED DISEASES INITIATIVE, Vision & Mission, http://www.dndi.org/about-
dndi/vision-mission/ (last visited May 5, 2016). 
 3. Patrice Trouiller et al., Drug Development for Neglected Diseases: A Deficient Market and a 
Public-Health Policy Failure, 359 THE LANCET 2188, 2191 (2002). 
 4. Id. 
 5. Philip Stevens, Diseases of Poverty and the 10/90 Gap, WORLD HEALTH ORG. (Nov. 2004), 
http://who.int/intellectualproperty/submissions/InternationalPolicyNetwork.pdf. 
 6. There is some disagreement over the number of neglected diseases. See infra Part II. Section 
A. 
 7. Patrice Trouiller et al., Drug development for neglected diseases: a deficient market and a 
public-health policy failure, PublicHealth 359 THE LANCET 2188 (2002).  
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.620.5966&rep=rep1&type=pdf. 
   8. Trouiller et al., supra note 3, at 2188. 
 9. WORLD HEALTH ORG. [WHO], Accelerating Work to Overcome the Global Impact of 
Neglected Tropical Diseases: A Roadmap for Implementation, WHO/HTM/NTD/2012.1 (2012), 
http://apps.who.int/iris/bitstream/10665/70809/1/WHO_HTM_NTD_2012.1_eng.pdf. 
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living in poverty, causing unique morbidity and mortality considerations 
such as stigma, discrimination, and perpetuated poverty; (2) the disease 
predominantly affects tropical areas; (3) the disease may be immediately 
controlled or eradicated through application of the five public health 
strategies adopted by the Department for Control of NTDs,10 or (4) the 
disease has generally been ignored by research initiatives and resource 
allocations. In order to qualify, a disease must either meet a combination of 
criteria (1), (2), and (3) or criteria (1), (2), and (4).11 
Overall, neglected diseases affect 1 billion people—about one-sixth of 
the world’s population—but neglected diseases are not proportionally 
addressed.12 These neglected diseases include: “Buruli ulcer disease, 
Chagas disease, dengue and chikungunya, dracunculiasis, echinococcosis, 
endemic treponematoses (yaws), foodborne trematodiases, human African 
trypanosomiasis, leishmaniasis, leprosy, lymphatic filariasis, 
onchocerciasis, rabies, schistosomiasis, soil-transmitted helminthiases, 
taeniasis/cysticercosis and trachoma.”13 Treatment regimens for these 
diseases fall under two categories: tool-ready, and “tool-deficient”, 
depending on how much research has been done, and how much more is 
needed to control the diseases.14 
This paper addresses the imbalance in the development of treatments 
for neglected diseases. It analyzes the causes behind the imbalances, and 
the current legal and societal initiatives that are in place to address the 
diseases. In particular, the paper suggests that the current patent system 
fails to effectively incentivize the development of treatment for neglected 
diseases. It further argues that the current international patent landscape 
creates some Band-Aid solutions to pharmaceutical access in developing 
countries in times of need, but does not adequately foster research and 
 
 10. These strategies include: “(i) preventive chemotherapy; (ii) innovative and intensified disease-
management; (iii) vector control and pesticide management; (iv) veterinary public health; and (v) 
provision of safe drinking water, sanitation, and hygiene education.” e-Recruitment- Scientist, Vector 
and Ecology Management (HQ.16/NTD/FT256), WORLD HEALTH ORG. (Oct. 22, 2016), 
https://erecruit.who.int/public/hrd-cl-vac-view.asp?o_c=1000&jobinfo_uid_c=33428&vaclng=en. 
 11. Recommendation for the Adoption of Additional Diseases as Neglected Tropical Diseases, 
WORLD HEATH ORG. (2013), 
http://www.who.int/neglected_diseases/diseases/Adoption_additional_NTDs.pdf?ua=1 [hereinafter 
WHO Recommendation]. 
 12. CTRS. FOR DISEASE CONTROL AND PREVENTION, Neglected Tropical Diseases, 
http://www.cdc.gov/globalhealth/ntd/ (last updated June 7, 2016). 
   13. See WHO Recommendation, supra note 10; but see Trouiller et al., supra note 3, at 2188. 
 14. For neglected tropical diseases, pocket change goes a long way, CTR. FOR HIGH IMPACT 
PHILANTHROPY (Sept. 14, 2010), http://endtheneglect.org/2010/09/for-neglected-tropical-diseases-0-40-
goes-a-long-way/. 
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development in these areas. As a result of these shortcomings, developing 
countries are unable to enhance their own research and manufacturing 
capacities to meet their unique drug needs, and pharmaceutical companies 
in developed countries lack incentives to develop treatment for diseases 
impacting the world’s poorest populations. Finally, this paper offers some 
recommendations about how the current status of treatment can be 
improved. 
II. BACKGROUND ON NEGLECTED TROPICAL DISEASES 
A. Neglected Diseases: What are they? 
There is some debate regarding the number of neglected diseases, and 
estimates range from twelve15 to over thirty.16 The World Health 
Organization has identified seventeen tropical neglected diseases as most 
important and the ones that it plans to focus on. The diseases are divided 
into four main groups of pathogens: (1) Protozoa (i.e. Chagas disease, 
human African trypanosomiasis, leishmaniases); (2) Bacteria (Buruli ulcer, 
leprosy, trachoma, yaws); (3) Helminths or Metazoan worms (i.e. 
cysticercosis/taeniasis, dracunculiasis, echinococcosis, foodborne 
trematodiases, lymphatic filariasis, onchocerciasis, schistosomiasis, soil-
transmitted helminthiasis); and (4) Viruses (dengue and chikungunya, 
rabies).17 As all of these are parasitic infections, NTDs occur most 
commonly in areas of poverty and poor sanitation, including areas with 
polluted water sources, livestock, and infection vectors.18 Many of these 
illnesses disproportionately impact women and children because these 
groups tend to be most in contact with disease agents.19 
Some of the diseases can be treated or prevented with existing 
technologies but have not yet been eliminated due to poor health policies 
and lack of organized action against the diseases. These tool-ready 
 
 15. Alan Fenwick, The Global Burden of Neglected Tropical Diseases, 3 PUBLIC HEALTH 233, 
234 (Mar. 2012). 
 16. Kamal K. Midha, Presidential Address at the FIP Congress Opening Ceremony, 25 INT’L 
PHARM. J. 4 (Dec. 2009), available at https://www.fip.org/files/fip/IPJ/IPJ_2009V25web.pdf. 
 17. Neglected Tropical Diseases, WORLD HEALTH ORG. (Nov. 24, 2015), 
http://www.who.int/neglected_diseases/diseases/en/. See also Lecture Notes: TROPICAL MEDICINE 
(Geoff Gill & Nick Beeching eds., 6th ed. 2011) (discussing the categorization of tropical diseases). 
 18. Neglected Tropical Diseases, WORLD HEALTH ORG. (Nov. 24, 2015), 
http://www.who.int/neglected_diseases/diseases/en/. 
 19. THE HENRY J. KAISER FAMILY FOUND., The U.S. Government and Global Neglected Tropical 
Disease Efforts (July 19, 2016), http://kff.org/global-health-policy/fact-sheet/the-u-s-government-and-
global-neglected-tropical-diseases/ [hereinafter KAISER]. 
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diseases, such as foodborne trematode infections, lymphatic filariasis, 
onchocerciasis, schistosomiasis, soil-transmitted helminthiases and 
trachoma could be prevented by coordinating large-scale, single-dose 
administration of therapies,20 such as vaccines, immune-booster pills, and 
other long-lasting treatment.21 For example, a four-drug concoction works 
to prevent up to seven diseases, but needs to be administered across a large 
population to control against re-contamination.22 Some regions already 
have control programs set up to provide mass drug administrations (or 
MDAs) to populations prone to the disease.23 Other NTDs such as Buruli 
ulcer, endemic treponematoses (yaws), leprosy (Hansen disease), Chagas 
disease, human African trypanosomiasis (sleeping sickness), leishmaniasis, 
cysticercosis and echinococcosis will require new technologies, tools and 
strategies to eliminate.24  Some of the diseases cannot be treated with 
existing MDA programs, or will require individual diagnostic and 
treatment mechanisms that involve more resources. Overall, the total cost 
of eliminating or eradicating neglected diseases from the world is estimated 
to be only $1.5 to 2 billion, if it is employed in conjunction with human 
resources and policy measures.25 This method of treatment would cost less 
than fifty cents per person per year but would require considerable 
governmental and private sector cooperation to organize and administer.26 
Section B. of this paper further discusses the governmental and social 
initiatives that could be implemented to accelerate the elimination of these 
diseases. 
 
 20. LORENZO SAVIOLOI ET AL., WORLD HEALTH ORG., A ROADMAP FOR IMPLEMENTATION 1 
(David W.T. Crompton ed. 2012), 
http://apps.who.int/iris/bitstream/10665/70809/1/WHO_HTM_NTD_2012.1_eng.pdf [hereinafter WHO 
ROADMAP]. 
 21. Jeffrey M. Bethony et al., Vaccines to Combat the Neglected Tropical Diseases, 239 
IMMUNOL REV. 237, 242–46 (2011). 
 22. SABIN VACCINE INST., The Solution, GLOBAL NETWORK| NEGLECTED TROPICAL DISEASES, 
http://www.globalnetwork.org/solution (last visited May 10, 2016). 
 23. SABIN VACCINE INST., The Most Common NTDs, GLOBAL NETWORK| NEGLECTED TROPICAL 
DISEASES, http://www.globalnetwork.org/neglected-tropical-diseases/fact-sheets (last visited Sept. 23, 
2016). 
 24. WHO ROADMAP, supra note 19, at 1; CTRS. FOR DISEASE CONTROL AND PREVENTION, 
Neglected Tropical Diseases, Other NTDs, 
http://www.cdc.gov/globalhealth/ntd/diseases/otherntds.html (last visited May 10, 2016). 
 25. Fenwick, supra note 14, at 235. 
 26. CTRS. FOR DISEASE CONTROL AND PREVENTION, Neglected Tropical Diseases—Fast Facts, 
http://www.cdc.gov/globalhealth/ntd/fastfacts.html (last visited May 4, 2016). 
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B. Current Legal and Social Initiatives in Place to Address Neglected 
Diseases 
Section 740 of the Agriculture, Rural Development, Food and Drug 
Administration, and Related Agencies Appropriation Act of 2010 
(Appropriation Act) states that the Commissioner of Food and Drugs of the 
U.S. Food and Drug Administration (FDA) shall establish a “review group 
which shall recommend . . . appropriate preclinical, trial design, and 
regulatory paradigms and optimal solutions for the prevention, diagnosis, 
and treatment of neglected diseases of the developing world.”27 In July 
2014, the FDA released its Guidance for Industry regarding Section 740 of 
the Appropriation Act. The FDA Guidance states that NTD applications 
will be reviewed as Investigative New Drug (IND) applications, regardless 
of where clinical trials take place. The same regulatory and review standard 
will be applied to NTD therapies as is applied to diseases endemic to the 
United States.28 Specifically, the Guidance gives the FDA “considerable 
latitude to exercise its scientific judgment to determine the kind and quality 
of data and information an applicant is required to provide . . . to meet the 
statutory standards” for NTD approval.29 The FDA commits to weigh the 
severity of the NTD against the quality of alternative therapies (or lack 
thereof) in determining whether the benefits of therapy outweigh risks.30 
Finally, the FDA acknowledges that certain circumstances may justify 
requiring only one, well-controlled clinical trial for approval of an NTD 
drug.31 
Section 524(b)(1) of the Food, Drug and Cosmetic (FD&C) Act 
formally acknowledges seventeen “tropical diseases” that have been 
neglected by traditional medical efforts.32 In addition, Section 524 of the 
FD&C Act introduces priority review vouchers for pharmaceutical 
manufacturers or sponsors that develop treatment for NTDs. A priority 
review voucher “entitles the holder of such voucher to priority review of a 
 
 27. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies 
Appropriation Act, Pub. L. No. 111-80, § 740(b) (2010). 
 28. U.S. DEP’T OF HEALTH AND HUMAN SERV., FOOD AND DRUG ADMIN., GUIDANCE FOR 
INDUSTRY NEGLECTED TROPICAL DISEASES OF THE DEVELOPING WORLD: DEVELOPING DRUGS FOR 
TREATMENT OR PREVENTION, 2 (2014), available at 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm269221
.pdf [hereinafter FDA GUIDANCE]. 
 29. Id. at 5; see also 21 C.F.R. § 314.105(c) (2008). 
 30. 21 C.F.R. § 312.84(a) (2008). 
 31. FDA GUIDANCE, supra note 27. 
 32. 21 U.S.C. § 360n(a)(3) (2016). 
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single human drug application submitted under section 355(b)(1) of this 
title or section 262 of title 42 after the . . . approval of the tropical disease 
product application.” Hence, the sponsor of the tropical disease application 
can use the voucher to expedite review of one of its more profitable 
drugs.33 These public policies have been geared toward diseases that do not 
have current treatment options, or need new vaccine generations. However, 
existing international patent laws impact drugs that are already available 
but expensive or unavailable in developing countries due to patent rights.34 
Between 1986 and 1994, World Trade Organization (WTO) drafted 
the Agreement on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS Agreement) to establish international standards for intellectual 
property rights and grant equal rights in all member countries.35 The TRIPS 
Agreement provides specific provisions relating to patents. First, it requires 
that patents be available in every field, including, pharmaceuticals and 
medical devices, which were previously not patentable in many countries.36 
Second, the national treatment provision requires countries to grant 
inventors from other countries the same rights as it grants to its own 
citizens. The most-favored-nation provision states that if a member nation 
grants one of its trading partners a special IP protection, it must grant that 
protection to all other member nations.37 
Some exceptions may be made for countries that need to provide their 
population with emergency “diagnostic, therapeutic and surgical 
methods.”38 Article 27 of TRIPS permits a suspension of patent rights to 
protect “ordre public or morality.” However, it has not been properly 
defined what constitutes “ordre public or morality” and the term continues 
to be debated.39 Article 30 permits “limited exceptions” to patent rights, 
granted they do not unreasonably interfere with the patent holder’s rights.40 
 
 33. 21 U.S.C. § 360n(a)(2) (2016). 
 34. Kyle Wamstad, Priority Review Vouchers: A Piece of the Incentive Puzzle, 14 VA. J.L. & 
TECH. 126, 135 (2009). 
 35. Intellectual property: protection and enforcement, WORLD TRADE ORG., 
https://www.wto.org/english/thewto_e/whatis_e/tif_e/agrm7_e.htm (last visited May 5, 2016). 
 36. Agreement on Trade Related Aspects of Intellectual Property Rights art. 27, Apr. 15, 1994, 33 
I.L.M. 81 [hereinafter TRIPS Agreement]. 
 37. Principles of the Trading System, WORLD TRADE ORG., 
https://www.wto.org/english/thewto_e/whatis_e/tif_e/fact2_e.htm#national (last visited Oct. 22, 2016). 
 38. UNIVERSITY OF KERALA DEPARTMENT OF LAW, Exclusion of Diagnostic, Therapeutic, and 
Surgical Methods from Patentability. 18 J. INTELL. PROP. RTS. 242, 242-50 (2013). 
 39. TRIPS Agreement, supra note 35, art. 27, at 93-94. 
 40. TRIPS Agreement, supra note 35, art. 30, at 95. 
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Article 31 allows exceptions for “national emergency or other 
circumstances of extreme urgency” where a government may circumvent 
patent rights without authorization of the right holder “for other use . . . of 
the subject matter of [the] patent,”41 implying “use other than that allowed 
under Article 30.”42 This article allows governments to occasionally grant 
compulsory licenses without negotiating with the patent owner, as long as 
the license is for a national emergency and noncommercial public use.43  A 
compulsory license authorizes the government or a third party country to 
manufacture a generic drug, with the condition that (1) it will 
predominantly supply the domestic market;44 and (2) the patent holder will 
be compensated based on the value of the license.45 
However, there is considerable debate regarding what constitutes a 
national emergency, and when this exception is permissible. The United 
States has insisted that developing countries are responsible for TRIPS 
provisions following 2005, which was the end of the adjustment grace 
period afforded to developing countries. However, developing countries 
argue that their economies are not prepared for a full-blown, U.S. style 
patent system, as they must prioritize other basic human needs such as 
affordable access to health care.46 
In response to this debate, member nations reconvened to resolve 
some of these controversies and questions, and created the 2001 Doha 
Declaration on TRIPS and Public Health (Doha Declaration).47 The Doha 
Declaration affirmed the importance of the “right to protect public health 
and, in particular, to promote access to medicines for all”, and affirmed 
“the right of WTO Members to use, to the full, the provisions in the TRIPS 
Agreement, which provide flexibility for this purpose.”48 In addition, the 
Doha Declaration clarified that each country has the right to define a 
 
 41. TRIPS Agreement, supra note 35, art. 31, at 95. 
 42. TRIPS Agreement, supra note 35, n.7, at 111. 
 43. TRIPS Agreement, supra note 35, art. 31(b), at 95. 
 44. TRIPS Agreement, supra note 35, art. 31(f), at 95. 
 45. TRIPS Agreement, supra note 35, art. 31(h), at 95. 
 46. See Kimberly A. Czub, Argentina’s Emerging Standard of Intellectual Property Protection: A 
Case Study of the Underlying Conflicts Between Developing Counties, TRIPS Standards, and the 
United States, 33 CASE W. RES. J. INT’L L. 191, 199–202 (2001); Robert C. Bird, Developing Nations 
and the Compulsory License: Maximizing Access to Essential Medicines While Minimizing Investment 
Side-Effects, 37 J.L. MED. & ETHICS 209, 210 (2009). 
 47. James Thuo Gathii, The Legal Status of the Doha Declaration on TRIPS and Public Health 
and the Vienna Convention on the Law of Treaties, 15 HARV. J.L. & TECH. 291, 292 (2009). 
 48. World Trade Organization, Ministerial Declaration of 14 November 2001, ¶ 4, WTO Doc. 
WT/MIN(01)/DEC/1, 41 ILM (2001), available at 
https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_e.pdf [hereinafter Doha Declaration]. 
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national emergency for itself, and that epidemics of any disease can always 
qualify as national emergencies. The Doha Declaration further clarified that 
compulsory licenses are permissible at any time during these national 
emergencies, even after a developing nation has fully adopted the TRIPS 
Agreement.49 Finally, recognizing that compulsory licenses may not be 
feasible for least developed nations that lack resources to manufacture the 
drugs, the Doha Declaration provided the option of parallel importation, 
which allows nations to import certain amounts of pre-made 
pharmaceuticals in return for reasonable compensation.50 Usually, the 
pharmaceutical companies will be able to sell the drugs cheaper in poorer 
countries, and recover costs with higher prices in developed countries.51 
Alternatively, third-party countries could apply for compulsory licenses, 
produce the biologic drugs, and provide them to least developed countries 
through parallel importation.52 
III. ARGUMENT/ANALYSIS 
A. Why Should We Care?: Impact of the Neglected Diseases on 
Communities—Overseas and In the United States 
The United States has fought long and hard to preserve the current 
status of international IP rights, which theoretically aims to gradually 
transfer all countries’ IP programs to look like the U.S.’s.53 While this 
might be a strong system in the long run, the U.S. and the rest of the world 
would benefit from a flexible and more country-specific IP system in the 
beginning, which later transitions into a uniform system. The concept of 
providing private companies incentives for developing novel, useful 
technologies has benefited several countries in promoting innovation.54 
This system could be used in a similar, but tailored way, to incentivize 
 
 49. Parallel Imports, WORLD HEALTH ORG. (May 12, 2016), 
http://www.who.int/trade/glossary/story070/en/. 
 50. Id. 
 51. Id. 
 52. C. James Attridge & Alexander S. Preker, IMPROVING ACCESS TO MEDICINES IN DEVELOPING 
COUNTRIES APPLICATION OF NEW INSTITUTIONAL ECONOMICS TO THE ANALYSIS OF MANUFACTURING 
AND DISTRIBUTION ISSUES, 28 (Mar. 2005), available at 
http://apps.who.int/medicinedocs/documents/s16743e/s16743e.pdf. 
 53. Robert C. Bird, Developing Nations and the Compulsory License: Maximizing Access to 
Essential Medicines While Minimizing Investment Side-Effects, 37 J.L. MED. & ETHICS 209, 210 
(2009). 
 54. Gene Quinn, The Story of How Patents Promote Innovation, IPWATCHDOG (May 12, 2014), 
http://www.ipwatchdog.com/2014/05/12/the-story-of-how-patents-promote-innovation/id=49520/. 
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innovation in developing countries. Implementing a flexible and tailored 
system according to each country’s developmental status and needs will 
benefit the entire world because developing countries will eventually be 
able to contribute more to technological advancements and emerge with 
stronger economies.55 
Furthermore, all countries in the world have an inherent self-interest in 
helping eliminate or control neglected diseases, which currently cause 
many young people to experience life-long disability, discrimination, 
stigma, and sometimes death.56 These living conditions lead communities 
into a state of distress, and prevent them from exiting poverty, leaving the 
community economically dependent on humanitarian efforts and 
government resources to pay for health care, food, and sanitation.57 In 
addition, the community is less productive and unable to contribute to the 
development of its country.58 Neglected diseases are also confounded with 
other diseases such as malaria, HIV, and tuberculosis, which causes 
heightened morbidity and mortality among people suffering from neglected 
diseases.59  Therefore, in order to see an expedited elimination of these 
three big diseases, it is important to address collateral disease factors, 
including neglected diseases.60 
The improvement in the health system of developing countries will 
lead to economic progress, which will in turn lead to a more robust IP 
system over time. The shift to a more U.S.-like patent system will benefit 
U.S. pharmaceutical companies, which will then be able to pursue more 
meaningful IP protection in foreign countries in the future. The local 
populations in developing countries will also be more financially capable 
of affording U.S.-developed pharmaceuticals.61 
Some scholars have argued that countries suffering from NTDs are of 
interest to the United States for foreign policy reasons; therefore, advancing 
 
 55. Ileana Dominguez-Urban, Harmonization in the Regulation of Pharmaceutical Research and 
Human Rights: The Need to Think Globally, 30 CORNELL INT’L L.J. 245, 253 (1997). 
 56. See generally, Id. 
 57. PETER J. HOTEZ, The Neglected Tropical Diseases and the Neglected Infections of Poverty: 
Overview of Their Common Features, Global Disease Burden and Distribution, New Control Tools, 
and Prospects for Elimination, in THE CAUSES AND IMPACTS OF NEGLECTED TROPICAL AND ZOONOTIC 
DISEASES: OPPORTUNITIES FOR INTEGRATED INTERVENTION STRATEGIES 221, 231-32 (2011), available 
at http://www.ncbi.nlm.nih.gov/books/NBK62521/. 
 58. WHO Recommendation, supra note 10, at 1. 
 59. Mike Shanahan, ‘Beat neglected diseases’ to fight HIV, TB and malaria, SCIDEV.NET (Jan. 
31, 2006), http://www.scidev.net/global/disease/news/beat-neglected-diseases-to-fight-hiv-tb-and-
mal.html. 
 60. Hoetz, supra note 57. 
 61. See generally Dominguez-Urban, supra note 53, at 253. 
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the elimination of NTDs would serve as a “low-cost yet high-profile” 
humanitarian effort for the U.S., with a high chance of success. Finally, 
Hotez and Thompson believe that poverty and isolation caused by NTDs 
promote conflicts in the world’s Islamic nations, which may possess 
nuclear weapons and could pose threats to the United States and their own 
regions.62 This threat of increased conflict adds urgency to the world’s 
purpose to ultimately eliminate NTDs. Collaborative research and 
development projects between the United States and Islamic countries to 
eliminate NTDs from unstable or conflict-ridden states and to develop a 
new generation of NTD vaccines, could build relationships between the 
regions, similar to the cooperation between the United States and former 
Soviet Union on polio and smallpox treatment development in the 20th 
century.63 
B. Reasons for the Lag in Treatment Development for Neglected Tropical 
Diseases 
Neglected diseases are a product of several factors, including a lack of 
governmental health initiatives, poor health policies, and misapplied patent 
laws. NTDs disproportionately impact low income countries, in Africa, 
Asia and South America, and tropical areas of the Caribbean.64 Because 
each neglected disease does not have a high death toll or rapid-onset death, 
they often do not receive wide-spread publicity or media attention. 
However, they often occur in combination with each other and lead to long-
term, debilitating conditions that prevent individuals from engaging in 
daily activities such as going to work or school.65 This traps the individuals 
in these communities in a cycle of poverty, whereby they continue to lack 
access to sanitary food, water and housing, which exposes them to more 
diseases.66 This paper briefly touches on the broad governmental and social 
factors that impact the status of neglected diseases; and then focuses 
particularly on IP factors that are preventing development of new treatment 
and prevention technologies for neglected diseases. 
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i. Social, Scientific and Governmental Actions That Hinder the 
Development of Neglected Disease Treatment 
Neglected diseases affect the world’s poorest and most vulnerable 
populations, and have been ignored due to a lack of political will, scientific 
advancement, and funds. For instance, NTDs represent a class of diseases 
that have especially complex genomes (particularly the eukaryotic67 
pathogens), making it a challenge to develop in vitro systems to maintain 
the NTD pathogens in the laboratory. It is also difficult to discover suitable 
animal models of the diseases, and adequate correlates of protection, such 
as antibodies.68 Without these experimental materials and methods, it is 
hard to develop antigens, adjuvants, and other platform technologies, 
making it challenging to manufacture an administrable treatment.69 In 
addition, many of these platform technologies are patented, therefore only 
available to richer populations.70 Some of the patent solutions discussed in 
the second part of this section will also address these scientific 
shortcomings. 
Due to the scientific complexity of NTDs, the cost of developing new 
technologies to address outbreaks is high. Because the diseases mostly 
impact people living in poverty, the target patients are not able to afford the 
price of the drugs. Even for tool-ready diseases, for which some form of 
treatment is available, governments do not have enough incentives to 
update treatment, coordinate mass-administration programs, or implement a 
system of diagnosis and treatment.71 
In contrast, diseases such as HIV/AIDS, malaria, and tuberculosis 
have received far more publicity and funding, through their prominent 
inclusion in the Millennium Development Goals, where neglected diseases 
were only referred to as “other diseases.”72 International efforts such as the 
U.S. President’s Emergency Plan for AIDS Relief , the U.S. President’s 
Malaria Initiative, and the Global Fund to Fight AIDS, Tuberculosis, and 
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Malaria, provided millions of people antiretrovirals, antimalarial drugs and 
insecticide-treated nets.73 Public private partnerships formed to develop and 
test new vaccines, through support from the Bill & Melinda Gates 
Foundation, the US National Institutes of Health, and the Wellcome 
Trust.74 As a result of the international effort to address these illnesses, the 
malaria mortality rate declined by 58% between 2000 and 2015. And, by 
2014, 13.6 million people globally were receiving antiretroviral therapy 
(ART) for HIV infection, while new infection rates dropped by 40%. Plus, 
nearly 37 million lives have been saved between 2000 and 2013 as a result 
of tuberculosis initiatives.75 
Other recent diseases, such as Zika and Ebola, have spread to 
the developed nations across the West, sparking international 
pressure and global efforts to develop a treatment.” Most NTDs do 
not spread quickly to developed nations, eliminating the immediate 
need for rich countries to invest in treatment development.76 For 
example, although parasitic infections account for one-third of the 
world’s total disease burden and are more prevalent in the 
developing world, they only account for 5% of diseases in the 
developed world.77 As international travel and trade increase, the 
world will be more at risk of diseases spreading rapidly on an 
international scale, pushing all countries to engage in a collaborative 
effort to reduce the impacts.78 
Hence, a successful solution to the neglected disease problem will 
have to be multi-faceted, and will likely include new regulation, social and 
humanitarian initiatives, and intellectual property (IP) reform.  These 
strategies for reform are discussed below. 
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ii. Current Patent Law and its Impact on Disease Treatment Development 
The TRIPs Agreement benefits countries and companies that 
introduce innovative products into the developing markets and wish to seek 
IP protection. For example, U.S. pharmaceutical companies can 
theoretically obtain patents for new pharmaceuticals in Asia and Africa, 
under similar patent terms as the U.S.79  However, many of these countries 
do not have the resources or infrastructure to invest in setting up a 
comprehensive patent system. For example, developing countries 
sometimes do not have IP offices and examiners to review patents, or 
courts and judges to enforce them. They may also have different cultural 
preferences, and not be interested in patent rights for medical instruments 
for moral reasons.80 Hence, many scholars have argued that the TRIPs 
Agreement favors a U.S.-style patent system and benefits developed 
countries, but is not best suited to meet the needs of developing countries. 
In addition, some scholars have argued that the current international IP 
scheme has hindered access to essential medicines in developing countries, 
because cheap generic versions of pharmaceuticals are slower to enter the 
market, and because developing countries are unable to conduct research to 
manufacture their own versions of medicines, due to over broad patenting 
by U.S. pharmaceutical companies and potential infringement issues.81 
However, the biggest issue in IP is the fact that the implementation 
has inhibited developing countries from taking full advantage of the 
principles of an IP system. While some previous scholarship has suggested 
that developing countries should disregard Western patenting ideals, it is 
advisable to implement a less stringent version of patent rights to jumpstart 
kick-start development of new technologies in emerging economies, and 
eventually in less developed countries. This method will be more effective 
than incentives such as the Doha Declaration, which allows countries to 
grant compulsory licenses and parallel importation. While current 
international initiatives such as the Doha Declaration provide some 
emergency access to already developed treatment, they are a Band-Aid 
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solution, and do not encourage local development of treatment. Therefore, 
this proposal also involves incentivizing U.S. pharmaceutical companies to 
invest more in solutions for neglected diseases.82 
IV. RECOMMENDATIONS 
One way in which U.S. patent law could indirectly benefit developing 
countries is through joint or collaborated research, and shared patent rights. 
Drugs for diseases effecting the developed world could be the basis for 
drugs that treat NTDs, and vice versa, as some diseases may be similar.83 
For example, Zika virus is in the same family at dengue and West Nile, and 
the current search for a vaccine for Zika is drawing on previous findings 
from the development of the dengue vaccine.84 Once a Zika vaccine is 
developed, the manufacturers will be best positioned to update the vaccine 
for use in dengue, and other water-associated mosquito diseases.85 
Additionally, diagnostic measures that are used for comparable diseases in 
the United States and other developed countries could be used for neglected 
diseases. However, many of these diagnostic procedures are patented, 
which inhibits affordable diagnostics in developing countries.86 
Second, another potential IP solution could involve treating different 
developing countries differently. The preamble to the WTO Agreement, 
which is the umbrella agreement for all WTO initiatives, including the 
TRIPs Agreement, “Recogniz[es] that . . . relations in the field of trade and 
economic endeavor should be conducted with a view to raising standards of 
living, ensuring full employment and a large and steadily growing volume 
of real income and effective demand, and expanding the production of and 
trade in goods and services, while allowing for the optimal use of the 
world’s resources in accordance with the objective of sustainable 
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development”.87 This differential treatment of countries based on their 
economic and development status would be justified by the WTO 
Agreement’s Preamble, which recognizes the “need for positive efforts 
designed to ensure that developing countries, and especially the least 
developed among them, secure a share in the growth in international trade 
commensurate with the needs of their economic development,” indicating 
that each developing country should be treated differently.88 The reason the 
U.S. patent system offers such a strong push for innovation is because the 
system was carefully tailored to meet the needs of this country. Hence, 
implementing a patent system that is unique to each developing country 
will enable both U.S., and developing countries, to acquire increased access 
to treatments but in a different manner. Instead of relying solely on imports 
and compulsory licenses, developing countries will be able to use their 
comparative advantages to set up manufacturing and innovation. 
Developing countries possess cheap raw materials, fewer regulations for 
clinical trials, and easier access to trial subjects, which will enable them to 
eventually set up comprehensive and locally beneficial research centers.89 
While developed countries could continue to operate under the current 
international patent framework, more flexible systems could be 
implemented in developing countries. For instance, one reason why many 
developing countries do not implement robust patent systems is because 
they are expensive to run. Conducting patent searches, tracking the filing 
process, and conducting examinations all require considerable resources. In 
addition, not all countries aspire to grant patents for all fields or products. 
Some countries exclude patents on food, agricultural products, and 
chemical compounds.90 In achieving a more user-friendly patent system, 
countries could lower the requirements for showing non-obviousness, could 
limit the kinds of products that patents are available for, and could reduce 
the number of years a patent term lasts. This would reduce the time to 
review and grant a patent, and would release the invention into the public 
domain in a shorter time frame. Implementing a system whereby local 
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researchers and manufacturers are enabled to conduct clinical trials will be 
a better long-term solution.91 
One way manufacturers are currently incentivized to develop drugs for 
neglected diseases is through Priority Review Vouchers (PRV). A drug 
manufacturer could get a PRV when it develops a treatment for a neglected 
disease or a disease primarily affecting the developing world. The 
manufacturer could apply the PRV to get priority review for one of its more 
profitable drugs, or a blockbuster drug. This could potentially increase a 
manufacturer’s profits by $300 million if it gains an extra six months on the 
market. This solution increases incentives for branded and reference 
product companies without extending patent terms or limiting generic 
entrance.92 However, it may be used with regards to patents too. For 
example, if a manufacturer develops a treatment for a neglected disease, 
upon approval of that diseases, the manufacturer could be entitled to a 
“priority examination voucher,” which could be used to hasten a patent 
application examination for a blockbuster drug or a more profitable 
invention.  
In addition, if a government wants to further incentivize 
implementation of the diseases treatment, it could condition the receipt of a 
priority examination voucher on the company ensuring that the neglected 
diseases treatment is property delivered and administered in an area of 
need. Furthermore, the government could also provide vouchers for slightly 
longer patent terms for another invention, if the manufacturing company 
offers to sponsor other activities such as sanitization or deworming in 
developing countries. 
V. CONCLUSION 
As the world becomes smaller and more interconnected, neglected 
diseases are a growing international concern that must be addressed 
through joint efforts between the developed and developing worlds. In 
particular, discrete patent systems for developing countries, joint patents 
and technology sharing agreements, and enhanced incentives for 
pharmaceutical companies will contribute to controlling and eliminating 
these diseases. Of course, these patent-related driving forces must he 
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accompanied by governmental and societal initiatives in order to arrive at a 
timely and comprehensive solution. 
 
